In Houston, a three-year-old boy whose liver cancer had spread to his lungs and bones—and returned after surgery and chemotherapy—entered an early human trial and emerged, twelve months later, without a trace of disease. The treatment, a form of CAR T cell therapy genetically engineered to hunt a protein found on liver cancer cells, had previously shown its power only against cancers of the blood. That it worked here, against a solid tumor in a small child, does not yet rewrite the map of pediatric oncology—but it marks, quietly and unmistakably, a new coordinate on it.
Experimental CAR T Therapy Achieves Complete Remission in Child With Metastatic Liver Cancer
A 3-year-old child with metastatic liver cancer achieved complete disease remission after experimental treatment, avoiding further chemotherapy and surgery.
Complete remission in a child whose cancer had already beaten chemotherapy and surgery.
Mark
So this child had metastatic cancer—it had spread—and chemotherapy and surgery didn't stop it. What changed when he got this CAR T therapy?
Mimi
The therapy took his own immune cells and rewired them to hunt a specific protein on his liver cancer cells. After two doses, the cancer disappeared entirely. He's been disease-free for a year.
Luke
One year is good, but we should be clear: this is one patient in an early trial. We don't know yet if the cancer will stay gone, or if other children will respond the same way.
Mark
Why is this different from regular immunotherapy?
Mimi
CAR T therapy is personalized—it's built from each patient's own cells. And it's engineered to target a specific marker on the cancer. The researchers also added genes to make the cells last longer and fight harder.
Luke
That's the theory. But we're watching two clinical trials now to see if it actually works in more patients. One success doesn't tell us the real safety profile or how often remission happens.
Mark
What makes this case special, then?
Mimi
Solid tumors have been the hard problem. CAR T worked well against blood cancers, but liver cancer is different—the cells are packed together. This boy's complete remission suggests the approach might work against solid tumors too.
Luke
And that's genuinely important. But the source material is honest: this is early. We need more data before anyone calls this a breakthrough.
Mark
What happens next?
Mimi
Two trials are running now—CARE at Baylor and IMPACT at Seattle Children's. They're enrolling more patients to see if this result holds up.
Luke
And that's the real story. The boy's remission is remarkable. Whether it's repeatable—that's what we're waiting to learn.
Le Pouls
- A toddler's cancer had outrun every standard weapon—three rounds of chemotherapy, three surgeries—and returned with new tumors in his lungs, leaving his doctors with no remaining conventional options.
- Researchers at Baylor College of Medicine reprogrammed the boy's own immune cells to recognize and destroy liver cancer cells, also arming them to produce proteins that help the engineered cells survive longer inside the body.
- Within weeks of his first infusion, scans showed the tumors retreating; after a second dose eight weeks later, imaging revealed only scar tissue where cancer had been.
- At twelve months, the child remains in complete remission—treated entirely as an outpatient, without the severe side effects that typically shadow aggressive cancer therapy.
- Scientists are cautious: two active clinical trials are now enrolling more patients to determine whether this single case is a turning point or a rare exception in the long struggle against solid tumor cancers.
In Houston, a three-year-old boy whose liver cancer had spread to his lungs and bones—and returned after surgery and chemotherapy—entered an early human trial and emerged, twelve months later, without a trace of disease. The treatment, a form of CAR T cell therapy genetically engineered to hunt a protein found on liver cancer cells, had previously shown its power only against cancers of the blood. That it worked here, against a solid tumor in a small child, does not yet rewrite the map of pediatric oncology—but it marks, quietly and unmistakably, a new coordinate on it.
A three-year-old boy with metastatic liver cancer is alive and disease-free after receiving an experimental immunotherapy—a result that may quietly shift how doctors approach solid tumors in children.
His diagnosis, hepatoblastoma, was aggressive from the start. The tumor in his liver was large, the disease had spread to his lungs and shown signs of reaching his bones, and he endured three rounds of chemotherapy and three surgeries before the cancer returned anyway. A new tumor appeared in his lungs, and the standard options were exhausted.
He then entered the CARE study, the first human trial of GPC3-CAR T cell therapy. Researchers took his own immune cells, genetically reengineered them to recognize glypican-3—a protein concentrated on liver cancer cells—and equipped them to produce two immune-boosting proteins designed to help them survive and fight more effectively. After his first infusion, scans showed the tumors shrinking and tumor markers falling. A second dose followed eight weeks later. Subsequent imaging found no remaining disease, only faint scarring. At twelve months, he remained cancer-free, treated entirely as an outpatient.
The case, published in The New England Journal of Medicine, carries weight because CAR T therapy has until now succeeded almost exclusively against blood cancers, where malignant cells circulate freely. Solid tumors cluster in dense tissue, making them far harder for engineered immune cells to penetrate. That this approach worked here suggests it might eventually reach other solid malignancies.
The researchers themselves are measured in their optimism. This is one patient in an early-phase trial. Two ongoing studies—CARE at Baylor College of Medicine and IMPACT at Seattle Children's Hospital—are now enrolling more patients to test whether this remission signals a new era or remains a remarkable exception. For now, it is proof that the approach can work.
A three-year-old boy with metastatic liver cancer is alive and disease-free after receiving two doses of an experimental immunotherapy—a result that marks a significant shift in how doctors might one day treat solid tumors in children.
The boy's cancer, hepatoblastoma, was aggressive from the start. When diagnosed, he carried a tumor in his liver measuring roughly 4.4 by 3.8 by 2.8 inches. The disease had already spread to his lungs and showed signs of reaching his bones. He endured three rounds of chemotherapy and underwent surgery to remove his primary liver tumor, followed by two additional operations to extract cancer from his lungs. For a time, the treatments seemed to work. Then the cancer came back, fast. A new tumor appeared in his lungs, and the standard playbook had run out of pages.
That's when he entered the CARE study, the first human trial of an experimental therapy called GPC3-CAR T cell treatment. The approach works by taking a patient's own immune cells—T cells—and reengineering them in the laboratory. Researchers added genes that allow these cells to recognize glypican-3, a protein that appears in high concentrations on liver cancer cells. They also equipped the cells with instructions to produce two immune-boosting proteins, interleukin-15 and interleukin-21, designed to help the engineered cells survive longer and kill tumors more effectively.
The boy received his first infusion of the modified cells. Within weeks, CT scans showed the tumors shrinking. Blood tests measuring alpha-fetoprotein, a marker of tumor activity, dropped. Eight weeks later, he received a second dose. The follow-up imaging told the story: no remaining disease, only faint scarring where tumors had been. At the twelve-month mark, he remained cancer-free.
This single case, published in The New England Journal of Medicine, matters because CAR T cell therapy has until now worked almost exclusively against blood cancers—leukemias and lymphomas where the cancer cells circulate through the bloodstream. Solid tumors, like those in the liver, present a different problem. The cancer cells cluster together in dense tissue, harder for engineered immune cells to penetrate and destroy. Success here suggests the approach might eventually extend to other solid malignancies.
David Steffin, the pediatric oncologist leading the work at Baylor College of Medicine in Houston, emphasized that the boy achieved complete remission entirely as an outpatient, without the severe side effects that sometimes accompany cancer treatment. His colleague Andras Heczey, from Seattle Children's Hospital, noted that the result points toward a potentially safer and more effective path for hepatoblastoma, a disease that ranks as the third leading cause of cancer death worldwide.
But the researchers themselves are careful about what this one success means. This is a single patient in an early-phase trial. Two ongoing studies—CARE at Baylor and IMPACT at Seattle Children's—are now enrolling more patients to test whether the result was a breakthrough or an outlier. The next months and years will determine whether this boy's remission signals a new era in pediatric cancer treatment or remains a remarkable exception. For now, it is proof that the approach can work.
Citations marquantes
This case demonstrates that a durable complete response in a chemotherapy-resistant solid tumor can be achieved entirely in the outpatient setting without systemic toxicity.— David Steffin, pediatric oncologist, Baylor College of Medicine
This study provides evidence that these novel CAR T cells may be a safe and effective modality for hepatoblastoma and highlights the need for further assessment in patients with GPC3+ solid tumors.— Andras Heczey, pediatric oncologist, Seattle Children's Hospital
Envie de l'histoire complète ?
Lire l'original sur ScienceAlert ↗
Health & Medicine